Market by Type, Delivery Mode, Application, End-user, Sales Channel, and Country Outlook | Forecast 2022-2028
A
Triton Market Research study shows that the market for immunoglobulin in the
Middle East and Africa would develop with a CAGR of 5.19% in the forecast years 2022-2028.
Report scope can be customized per your requirements. Request For Customization
The countries studied in the
market include:
• United Arab Emirates
• Saudi Arabia
• South Africa
• Turkey
• Rest of Middle East & Africa
Factors
such as strategic initiatives by top market players have significantly aided in
boosting the demand for immunoglobulin in the Middle East and Africa. Moreover,
the region witnessed innumerable product developments and launches, along with
the growth of the pharmaceutical industry, R&D activities, increase in
clinical trials, and significant investments in the biotechnology sector, which
have contributed to the growth of the immunoglobulin market in the Middle East
and Africa.
Turkey
witnessed notable growth in the pharmaceutical sector, which is further
expected to contribute to the growth of the immunoglobulin market. According to
the Pharmaceuticals Manufacturers Association of Turkey, there has been a 19.9%
growth in the pharma and medicinal products market. The vast shift in this
market from $1.14 billion in 2015 to $3.17 billion in 2020 is expected to
greatly aid the demand for immunoglobulin. Also, the pharma and medicinal
products market reached 2.21 billion units in 2015 to 2.43 billion units in
2020, fueling the demand for immunoglobulin-based treatments to cater to
different diseases and disorders. Thus, these factors are augmenting the
market’s growth significantly.
The
growth of the biotechnology sector in South Africa is fostering the immunoglobulin
market. For instance, in 2021, BixBio, an African genomics startup, gained a
large amount of funding from the Illumina Accelerator. The company is a
biotechnology startup focusing on unlocking the potential of a wide array of
genetic data while developing and expanding in precision medicine.
Additionally, the contribution from Cipla to invest $80.81 million in a biotech
plant to produce affordable cancer drugs is expected to promote the market’s
growth.
Intravenous
immunoglobulin is a blood product prepared from the serum of between 1,000 and
15,000 donors per batch. This type of treatment is commonly undertaken for
patients with antibody deficiencies. The intravenous immunoglobulin treatment
combines immunoglobulins donated by different people for treating different
conditions. It is used for minimizing the effects of inflammatory conditions
such as autoimmune diseases. Besides, it is also used to treat various
conditions such as lupus, myositis, vasculitis, antiphospholipid syndrome, etc.
The studied report evaluates
the market’s growth based on type, delivery mode, application, end-user, and
sales channel. Here, the delivery mode segment
comprises intravenous, subcutaneous, and intramuscular.
Key
players in the immunoglobulin market include Octapharma AG, CSL Behring, Adma
Biologics, Bio Products Laboratory, Takeda Pharmaceutical Company Limited,
Grifols SA, LFB Group, and Sichuan Yuanda Shuyang Pharmaceutical Co Ltd.
Pfizer
Inc is a multinational pharmaceutical and biotechnology corporation. The
company produces and develops vaccines and medicines for cardiology, oncology,
endocrinology, immunology, and neurology. Moreover, the company has two
business segments, Pfizer Biopharmaceuticals Group and Upjohn. The former deals
in medicines, vaccines, and biosimilars to treat various diseases, while Upjohn
offers products that treat non-communicable diseases. The company has a notable
business presence across the Middle East and Africa.
Key deliverables of the report:
● Market CAGR during the forecasting years 2022-2028
● Detailed data highlighting key insights, industry components, and
market strategies
● Comprehensive information and estimation of the immunoglobulin market
revenue growth in the Middle East and Africa and its influence on the parent market
● In-depth study of forthcoming trends in consumer behavioral patterns
● A meticulous analysis of the competitive landscape, vendor scorecard,
and Porter’s Five Forces Model
● A wide-ranging study of factors that will challenge the Middle East and
Africa immunoglobulin market’s growth during the upcoming years
Want
to get specific insights? Our team of analysts can customize this report based
on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. MIDDLE
EAST AND AFRICA IMMUNOGLOBULIN MARKET – SUMMARY
2. INDUSTRY
OUTLOOK
2.1. IMPACT
OF COVID-19 ON THE IMMUNOGLOBULIN MARKET
2.2. KEY
INSIGHTS
2.2.1. DEVELOPMENT
OF NEW PURIFICATION METHODS
2.2.2. INCREASING
PREFERENCE FOR PERSONALIZED MEDICINES
2.3. PORTER’S
FIVE FORCES ANALYSIS
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTES
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. THREAT
OF COMPETITIVE RIVALRY
2.4. MARKET
ATTRACTIVENESS INDEX
2.5. VENDOR
SCORECARD
2.6. KEY
MARKET STRATEGIES
2.6.1. PRODUCT
LAUNCHES & DEVELOPMENTS
2.6.2. PARTNERSHIPS
& AGREEMENTS
2.7. MARKET
DRIVERS
2.7.1. GROWTH
IN THE GERIATRIC POPULATION
2.7.2. PREVALENCE
OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS
2.7.3. INCREASING
RESEARCH AND DEVELOPMENT ACTIVITIES
2.8. MARKET
CHALLENGES
2.8.1. HIGH
COST OF THERAPY
2.8.2. HIGH
RISK OF SIDE EFFECTS DUE TO THE USE OF IMMUNOGLOBULIN
2.9. MARKET
OPPORTUNITIES
2.9.1. INCREASING
ADOPTION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) TREATMENTS
2.9.2. GROWING
CLINICAL TRIALS
3. MIDDLE
EAST AND AFRICA IMMUNOGLOBULIN MARKET OUTLOOK – BY TYPE
3.1. IGG
3.2. IGA
3.3. IGM
3.4. IGE
3.5. IGD
4. MIDDLE
EAST AND AFRICA IMMUNOGLOBULIN MARKET OUTLOOK – BY DELIVERY MODE
4.1. INTRAVENOUS
4.2. SUBCUTANEOUS
4.3. INTRAMUSCULAR
5. MIDDLE
EAST AND AFRICA IMMUNOGLOBULIN MARKET OUTLOOK – BY APPLICATION
5.1. HYPOGAMMA
GLOBULINEMIA
5.2. CHRONIC
INFLAMMATORY DEMYELINATING POLYNEUROPATHY
5.3. PRIMARY
IMMUNODEFICIENCY DISEASES
5.4. MYASTHENIA
GRAVIS
5.5. MULTIFOCAL
MOTOR NEUROPATHY
5.6. IDIOPATHIC
THROMBOCYTOPENIC PURPURA (ITP)
5.7. INFLAMMATORY
MYOPATHIES
5.8. SPECIFIC
ANTIBODY DEFICIENCY
5.9. GUILLAIN-BARRE
SYNDROME
5.10. OTHER
APPLICATIONS
6. MIDDLE
EAST AND AFRICA IMMUNOGLOBULIN MARKET OUTLOOK – BY END-USER
6.1. HOSPITALS
& CLINICS
6.2. HOMECARE
7. MIDDLE
EAST AND AFRICA IMMUNOGLOBULIN MARKET OUTLOOK – BY SALES CHANNEL
7.1. HOSPITAL
PHARMACY
7.2. SPECIALTY
PHARMACY
7.3. OTHER
SALES CHANNELS
8. MIDDLE
EAST AND AFRICA IMMUNOGLOBULIN MARKET – COUNTRY OUTLOOK
8.1. UNITED
ARAB EMIRATES
8.2. SAUDI
ARABIA
8.3. TURKEY
8.4. SOUTH
AFRICA
8.5. REST
OF MIDDLE EAST & AFRICA
9. COMPETITIVE
LANDSCAPE
9.1. BIOTEST
AG
9.2. CHINA
BIOLOGIC PRODUCTS INC
9.3. GRIFOLS
SA
9.4. LFB
GROUP
9.5. CSL
BEHRING
9.6. KEDRION
BIOPHARMA
9.7. OCTAPHARMA
AG
9.8. TAKEDA
PHARMACEUTICAL COMPANY LIMITED
9.9. BIO
PRODUCTS LABORATORY
9.10. SHANGHAI
RAAS BLOOD PRODUCTS CO LTD
9.11. PFIZER
INC
9.12. SANQUIN
PLASMA PRODUCTS BV
9.13. ADMA
BIOLOGICS
9.14. SICHUAN
YUANDA SHUYANG PHARMACEUTICAL CO LTD
9.15. KAMADA
LTD
10. RESEARCH
METHODOLOGY & SCOPE
10.1. RESEARCH
SCOPE & DELIVERABLES
10.2. SOURCES
OF DATA
10.3. RESEARCH
METHODOLOGY
TABLE 1: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 4: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 5: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 6: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 7: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)
TABLE 8: MIDDLE EAST AND AFRICA
IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
FIGURE 1: MARKET
ATTRACTIVENESS INDEX
FIGURE 2: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY TYPE, 2021 & 2028 (IN %)
FIGURE 3: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY IGG, 2022-2028 (IN $ MILLION)
FIGURE 4: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY IGA, 2022-2028 (IN $ MILLION)
FIGURE 5: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY IGM, 2022-2028 (IN $ MILLION)
FIGURE 6: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY IGE, 2022-2028 (IN $ MILLION)
FIGURE 7: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY IGD, 2022-2028 (IN $ MILLION)
FIGURE 8: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2021 & 2028 (IN %)
FIGURE 9: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY INTRAVENOUS, 2022-2028 (IN $ MILLION)
FIGURE 10: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS, 2022-2028 (IN $ MILLION)
FIGURE 11: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR, 2022-2028 (IN $ MILLION)
FIGURE 12: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2021 & 2028 (IN %)
FIGURE 13: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2028 (IN $
MILLION)
FIGURE 14: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING
POLYNEUROPATHY, 2022-2028 (IN $ MILLION)
FIGURE 15: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2028
(IN $ MILLION)
FIGURE 16: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2028 (IN $ MILLION)
FIGURE 17: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2028 (IN $
MILLION)
FIGURE 18: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP),
2022-2028 (IN $ MILLION)
FIGURE 19: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2028 (IN $
MILLION)
FIGURE 20: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2028 (IN $
MILLION)
FIGURE 21: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2028 (IN $
MILLION)
FIGURE 22: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2028 (IN $ MILLION)
FIGURE 23: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY END-USER, 2021 & 2028 (IN %)
FIGURE 24: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2028 (IN $
MILLION)
FIGURE 25: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2028 (IN $ MILLION)
FIGURE 26: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2021 & 2028 (IN %)
FIGURE 27: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2028 (IN $ MILLION)
FIGURE 28: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2028 (IN $ MILLION)
FIGURE 29: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, BY OTHER SALES CHANNELS, 2022-2028 (IN $ MILLION)
FIGURE 30: MIDDLE EAST AND
AFRICA IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)
FIGURE 31: UNITED ARAB
EMIRATES IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 32: SAUDI ARABIA
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 33: TURKEY
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 34: SOUTH AFRICA
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 35: REST OF MIDDLE EAST
& AFRICA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)